ClinicalTrials.Veeva

Menu

Non-interventional Follow-up Versus Fluid Bolus in RESPONSE to Oliguria in the Critically Ill

H

Helsinki University Central Hospital (HUCH)

Status

Completed

Conditions

Critically Ill
Oliguria
Acute Kidney Injury
Sepsis

Treatments

Other: fluid bolus
Other: follow-up without intervention

Study type

Interventional

Funder types

Other

Identifiers

NCT02860572
200/13/03/02/16

Details and patient eligibility

About

Background: After hypotension, oliguria (urine output less than 0.5 mL/kg/h) was the most common trigger to administer fluid bolus in a multinational practice survey in intensive care. The effect of fluid bolus on cardiovascular variables can be very short-lived among patients in shock suggesting that fluid boluses in the optimization phase are unlikely to improve patient-centered outcomes. Moreover, a growing body of evidence suggests a poor renal response to fluid bolus.

Objective: To investigate, whether fluid bolus - as a standard of care - improves urine output in oliguric patients compared to a non-interventional follow-up approach without fluid bolus.

Design: Investigator-initiated, open, randomized, controlled study

Interventions:

  1. Intervention group - follow-up without intervention
  2. Control group - fluid bolus (500mL of balanced crystalloid over 30 minutes)

Randomization: 1:1 stratified according to the site, presence of acute kidney injury, and sepsis

Trial size: 130 patients randomized in 2 ICUs

Full description

Study hypothesis:

The investigators hypothesize that fluid bolus given due to oliguria does not improve urine output in a majority of patients, especially among those with acute kidney injury. Another study hypothesis is that patients receiving fluid bolus will have higher levels of endothelial damage biomarkers.

Intervention description:

Intervention group -follow-up without intervention; No intervention to increase the urine output within 2 hours will be done.

Standard group - Fluid bolus group: Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.

In both groups, if severe hemodynamic instability occurs, a rescue bolus of 500mL over 30 minutes may be given according to the decision of the treating clinician.

In both groups, all other ongoing infusions (nutrition and on-going clear fluids) will be held constant during the 2-hour period. Vasoactive medications, sedation, short-acting insulin, and other medications can be modified according the clinical need. No diuretics during the 2-hour study period are allowed. After two hours from randomization, treating clinician can modify the fluid and drug therapy according to the clinical needs of the patient. All administered fluids will be recorded 6 h from randomization.

Except for the study intervention period of 2 hours, no attempt to control fluid therapy will be done. During the study period, all other aspects of critical care will follow the ICU's standard operating procedures and clinician's prescription.

Enrollment

130 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age over 18
  • Emergency admission to an ICU
  • Mean arterial pressure (MAP) >65 mmHg (with vasopressors if needed) and initial fluid resuscitation for shock/hypovolemia has been given
  • Oliguria (urine output less than 0.5mL/kg/h) for at least 2 consecutive hours

Exclusion criteria

  • Marked fluctuations in hemodynamics within last 2 hours (cardiac arrhythmias, increase in norepinephrine need over 0.2ug/kg/min, need for initiation of inotrope/inodilator)
  • Administration of furosemide within last 6 hours
  • Chronic kidney disease (estimated pre-critical illness GFR < 60ml/min/1.73m2)
  • Renal replacement therapy
  • Among patients with acute kidney injury, urgent indications for commencing renal replacement therapy
  • Fluid overload (cumulative fluid accumulation exceeds 10% of baseline body weight)
  • Pulmonary edema (bilateral infiltrates in chest x-ray)
  • Active bleeding (need for transfusion, platelets, or fresh frozen plasma)
  • Suspected or known intra-abdominal hypertension (IAP >16mmHg)
  • Pregnant or lactating
  • Expected survival less than 24h
  • Obtaining informed consent is not possible/consent is denied

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

130 participants in 2 patient groups

follow-up without intervention
Experimental group
Description:
No intervention to increase the urine output within 2 hours will be done.
Treatment:
Other: follow-up without intervention
Standard group - fluid bolus
Active Comparator group
Description:
Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.
Treatment:
Other: fluid bolus

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems